Genomic alterations in circulating tumor DNA (ctDNA) and response to telisotuzumab adizutecan (ABBV-400) treatment in patients (pts) with colorectal cancer (CRC). A comparison of real-world outcomes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback